La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
76 hedge funds and large institutions have $88.1M invested in La Jolla Pharmaceutical Company in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 6 closing their positions.
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
17% more funds holding
Funds holding: 65 → 76 (+11)
12% more capital invested
Capital invested by funds: $78.8M → $88.1M (+$9.29M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
61% less call options, than puts
Call options by funds: $114K | Put options by funds: $294K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$1.91M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.74M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$1.43M |
| 4 |
Millennium Management
New York
|
+$969K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$633K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.08M |
| 2 |
Renaissance Technologies
New York
|
-$531K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$383K |
| 4 |
RI
RTW Investments
New York
|
-$383K |
| 5 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$366K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
Alyeska Investment Group
Chicago,
Illinois
| – | -$2.08M | -536,847 | Closed |
|
77
Ameriprise
Minneapolis,
Minnesota
| – | -$134K | -34,495 | Closed |
|
78
Walleye Capital
New York
| – | -$69 | -17,901 | Closed |
|
79
Citadel Advisors
Miami,
Florida
| – | -$65K | -11,801 | Closed |
|
80
Russell Investments Group
London,
United Kingdom
| – | -$21K | -5,568 | Closed |
|
LJPC Hedge Fund Activity: Q1 2021 in Review
76 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q1 2021, worth a combined $88.1M — up 12% from $78.8M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new LJPC positions and 6 closed out — a net gain of 11 holders — while 16 added to existing stakes and 22 trimmed.
The largest buyer was Wells Fargo, adding an estimated $1.91M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $2.08M sold.
- 76 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q1 2021, up from 65 in Q4 2020.
- Funds reported $88.1M of La Jolla Pharmaceutical Company stock for Q1 2021, up 12% quarter-over-quarter.
- 17 funds opened new La Jolla Pharmaceutical Company positions in Q1 2021 and 6 closed out, a net change of +11 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q1 2021 was Wells Fargo, an estimated $1.91M added.
- The largest La Jolla Pharmaceutical Company seller in Q1 2021 was Alyeska Investment Group, an estimated $2.08M sold.
Based on aggregated 13F filings for Q1 2021.